Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate is a phase 2, interventional study registered as NCT07344220 by Hoag Memorial Hospital Presbyterian, with a registry enrolment figure of 39 participants, started 2026-03-05 and due to reach its primary completion in 2028-11. Interventions recorded: DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg. Conditions listed: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer. Primary outcome: Recommended Phase 2 Dose (RP2D); Incidence of Dose Limiting Toxicities (DLTs). Pancreatic eligibility wording from the registry: "Histopathologically confirmed diagnosis of metastatic pancreatic adenocarcinoma who completed 4 months or more of first line chemotherapy and have achieved at least SD documented by CT scan". Sites: United States. No results are recorded here; the registry entry is the source.